Beyond Heparin and Aspirin: Evolving Paradigms in Anticoagulant Management of Obstetric Antiphospholipid Syndrome

Abstract

Our knowledge of antiphospholipid antibodies and their impact on pregnancy continues to evolve. A variety of antiphospholipid antibodies have been identified but not all of them seem to be pathologic for pregnancy outcome. Our understanding of which patients are at high risk for adverse pregnancy outcome and the most effective treatment will require clinical trials based on risk stratification and long-term follow-up of infants.